Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
general
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Nature Communications, Volume 14, No. 1, Article 6182, Year 2023
Notification
URL copied to clipboard!
Description
In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB). We estimated the global burden of RR-TB over the lifetime of affected individuals. We synthesized data on incidence, case detection, and treatment outcomes in 192 countries (99.99% of global tuberculosis). Using a mathematical model, we projected disability-adjusted life years (DALYs) over the lifetime for individuals developing tuberculosis in 2020 stratified by country, age, sex, HIV, and rifampicin resistance. Here we show that incident RR-TB in 2020 was responsible for an estimated 6.9 (95% uncertainty interval: 5.5, 8.5) million DALYs, 44% (31, 54) of which accrued among TB survivors. We estimated an average of 17 (14, 21) DALYs per person developing RR-TB, 34% (12, 56) greater than for rifampicin-susceptible tuberculosis. RR-TB burden per 100,000 was highest in former Soviet Union countries and southern African countries. While RR-TB causes substantial short-term morbidity and mortality, nearly half of the overall disease burden of RR-TB accrues among tuberculosis survivors. The substantial long-term health impacts among those surviving RR-TB disease suggest the need for improved post-treatment care and further justify increased health expenditures to prevent RR-TB transmission. © 2023, Springer Nature Limited.
Authors & Co-Authors
Menzies, Nicolas A.
United States, Boston
Harvard T.h. Chan School of Public Health
Allwood, Brian William
South Africa, Tygerberg
Tygerberg Hospital
Dean, Anna S.
Switzerland, Geneva
Organisation Mondiale de la Santé
Dodd, P. J.
United Kingdom, Sheffield
The University of Sheffield
Houben, Rein M.G.J.
United Kingdom, London
London School of Hygiene & Tropical Medicine
Knight, Gwenan M.
United Kingdom, London
London School of Hygiene & Tropical Medicine
Meghji, Jamilah Z.
United Kingdom, London
Imperial College London
Rachow, Andrea
Germany, Munich
Ludwig-maximilians-universität München
Germany, Munich
Partner Site Munich
Germany, Oberschleissheim
Helmholtz Center Munich German Research Center for Environmental Health
Schumacher, Samuel G.
Switzerland, Geneva
Organisation Mondiale de la Santé
Mirzayev, Fuad
Switzerland, Geneva
Organisation Mondiale de la Santé
Cohen, Ted
United States, New Haven
Yale University
Statistics
Citations: 1
Authors: 11
Affiliations: 11
Identifiers
Doi:
10.1038/s41467-023-41937-9
ISSN:
20411723
Research Areas
Disability
Infectious Diseases
Study Design
Cohort Study